Canada Markets open in 7 hrs 25 mins

Medexus Pharmaceuticals Inc. (MEDXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.3800-0.0600 (-2.46%)
At close: 03:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.4400
Open2.4600
BidN/A x N/A
AskN/A x N/A
Day's Range2.3700 - 2.4600
52 Week Range1.2500 - 3.5000
Volume52,010
Avg. Volume7,795
Market Cap46.826M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-1.1230
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • GlobeNewswire

    Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

    Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023 Management to host conference call at 8:00 AM Eastern Time on Tuesday, August 9, 2022 TORONTO and CHICAGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s first fisc

  • GlobeNewswire

    Medexus Schedules First Quarter 2023 Conference Call

    TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022 to discuss Medexus’s results for its first quarter ended June 30, 2022. Medexus expects to file its financial statements and MD&A after markets close on August 8, 2022. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011

  • GlobeNewswire

    Treosulfan NDA Resubmitted to FDA

    FDA decision expected within six months of acceptancePivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO and CHICAGO, July 25, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for treosulfan (NDA) with the U.S. Food and Drug Administration (FDA). The current submission was a response to the FDA